Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
McKesson
Covington
Queensland Health
US Army
Boehringer Ingelheim
Citi
Healthtrust

Generated: November 17, 2018

DrugPatentWatch Database Preview

Enasidenib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for enasidenib mesylate and what is the scope of enasidenib mesylate patent protection?

Enasidenib mesylate is the generic ingredient in one branded drug marketed by Celgene Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for enasidenib mesylate
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 30
Patent Applications: 35
DailyMed Link:enasidenib mesylate at DailyMed
Pharmacology for enasidenib mesylate
Synonyms for enasidenib mesylate
1446502-11-9
1650550-25-6
2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol
2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol
2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-
2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, methanesulfonate (1:1)
3T1SS4E7AG
69Q
AG 221
AG-221
AG-221 (Enasidenib)
AG-221 mesylate
AG-221; Enasidenib
AG-221(Enasidenib)
AG221
AK431837
AKOS026750439
CC 90007
CC-90007
CC-90007 Free Base
CC90007
CS-5017
CS-7541
D10901
DB13874
Enasidenib
Enasidenib (mesylate)
Enasidenib (USAN/INN)
Enasidenib [INN]
Enasidenib [USAN:INN]
Enasidenib mesilate
Enasidenib mesylate [USAN]
Enasidenib methanesulfonate
EX-A654
FT-0700204
GTPL8960
HY-18690
HY-18690A
IDHIFA
Idhifa (TN)
J-690181
KB-3356927
KS-000006AW
MFCD29472245
s8205
SCHEMBL15102202
SCHEMBL16448052
UF6PC17XAV
UNII-3T1SS4E7AG
UNII-UF6PC17XAV
ZINC222731806

US Patents and Regulatory Information for enasidenib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cipla
McKesson
Covington
Queensland Health
US Army
Boehringer Ingelheim
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.